Byetta Lawsuits Move Forward, as Federal and State Incretin Mimetics...
The Firm is investigating Byetta lawsuits that allege an association between the use of Byetta and pancreatic cancer, as well as pancreatitis and thyroid cancer.(PRWeb January 25, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11521828.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 25, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: More Than 260 Product Liability Claims Now...
The Firm is investigating Byetta lawsuits on behalf of individuals who developed pancreatic cancer, pancreatitis, or thyroid cancer, allegedly due to their use of Byetta.(PRWeb January 16, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11496700.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 17, 2014 Category: Pharmaceuticals Source Type: news

Bernstein Liebhard LLP Notes Progress in Federal Byetta Lawsuit...
The attorneys at Bernstein Liebhard LLP are actively investigating potential Byetta lawsuit claims alleging pancreatic cancer, pancreatitis and thyroid cancer caused by the diabetes medication.(PRWeb December 22, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11442741.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 23, 2013 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of...
The Firm is investigating potential Byetta lawsuits on behalf of alleged victims of Byetta and pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb December 03, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11388186.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 4, 2013 Category: Pharmaceuticals Source Type: news

Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Issuance...
The Firm is currently investigating Byetta lawsuits that allege an association between use of Byetta and pancreatic cancer, as well as pancreatitis and thyroid cancer.(PRWeb November 16, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11339864.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 19, 2013 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status...
The Firm is evaluating potential Byetta lawsuits alleging an association between the use of Byetta and pancreatic cancer.(PRWeb November 08, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11316884.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 10, 2013 Category: Pharmaceuticals Source Type: news

New York Attorney Now Accepting Januvia, Janumet, Byetta or...
Commack, New York law firm, Rudolph F.X. Migliore, P.C., is accepting cases from individuals who took the prescription medication Januvia, Janumet, Byetta or Victoza and later developed pancreatic...(PRWeb November 05, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11297852.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 5, 2013 Category: Pharmaceuticals Source Type: news

GLP-1, TZD Combo May Cut Heart Risk (CME/CE)
(MedPage Today) -- The GLP-1 agonist exenatide (Byetta, Bydureon) may temper the cardiovascular risks associated with rosigltiazone (Avandia), possibly via its effects on a clotting pathway, a database study suggests. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 9, 2013 Category: Cardiology Source Type: news

Byetta Lawsuit News: Bernstein Liebhard LLP Notes Establishment of...
Byetta lawsuits pending in the new multidistrict litigation allege the drug’s makers failed to warn of a possible connection between Byetta and pancreatic cancer.(PRWeb August 27, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11065921.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 28, 2013 Category: Pharmaceuticals Source Type: news

Byetta May Help in Type 1 Diabetes, Too (CME/CE)
(MedPage Today) -- The GLP-1 agonist exenatide (Byetta) used in type 2 diabetes may have metabolic effects on patients with type 1 disease, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 14, 2013 Category: Cardiology Source Type: news

Byetta Lawsuit Investigation Being Conducted by Bernstein Liebhard LLP...
Dozens of Byetta lawsuits now pending in federal court allege the drug’s makers failed to warn of a possible connection between Byetta and pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb August 10, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11015808.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 11, 2013 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit - Claims Move Forward, as Panel Considers Consolidation...
The Firm is investigating alleged Byetta pancreatic cancer lawsuits, as well as claims involving Byetta and pancreatitis and thyroid cancer.(PRWeb July 26, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb10969663.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 27, 2013 Category: Pharmaceuticals Source Type: news

Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Former Eli Lilly executive brings wealth of diabetes insights, business strategy and global pharma leadership experience to Intarcia during critical time of opportunity BOSTON, July 26, 2013 -- (Healthcare Sales & Marketing Network) -- Intarcia Therape... Biopharmaceuticals, Drug Delivery, PersonnelIntarcia Therapeutics, ITCA 650, exenatide (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 26, 2013 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: Bernstein Liebhard LLP Awaits Decision on...
The Firm is investigating Byetta lawsuits on behalf of individuals treated with the type 2 diabetes drug who went on to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb July 20, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb10948003.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 22, 2013 Category: Pharmaceuticals Source Type: news

Byetta Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on...
The Firm is investigating Byetta lawsuits on behalf of individuals treated with the type 2 diabetes drug who went on to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb July 13, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb10925201.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 13, 2013 Category: Pharmaceuticals Source Type: news

Byetta Lawsuits Move Forward, as Judicial Panel Considers...
The Firm is investigating lawsuits on behalf of alleged victims of Byetta pancreatitis, Byetta pancreatic cancer, or Byetta thyroid cancer.(PRWeb July 08, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb10906203.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 9, 2013 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit Website Launched by Bernstein Liebhard LLP Provides...
The Firm is currently investigating Byetta lawsuit claims on behalf of patients who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer after taking the type 2 diabetes medication.(PRWeb June 28, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb10884421.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 30, 2013 Category: Pharmaceuticals Source Type: news

The therapeutic virtues of venom
This article appeared in Guardian Weekly, which incorporates material from Le MondeMedical researchBiochemistry and molecular biologyZoologyPharmaceuticals industryWildlifeVahé Ter Minassianguardian.co.uk © 2013 Guardian News and Media Limited or its affiliated companies. All rights reserved. | Use of this content is subject to our Terms & Conditions | More Feeds     (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 21, 2013 Category: Science Authors: Vahé Ter Minassian Tags: Pharmaceuticals industry Medical research Features Guardian Weekly Zoology Environment Biochemistry and molecular biology Business Science Wildlife Source Type: news

Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments...
The Firm is investigating Byetta lawsuits on behalf of type 2 diabetics who developed pancreatic cancer, pancreatitis, or thyroid cancer, allegedly due to Byetta.(PRWeb June 20, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb10854869.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 21, 2013 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: Bernstein Liebhard LLP Comments on American...
The Firm is investigating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer, or thyroid cancer while using this medication.(PRWeb June 19, 2013)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb10849904.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 21, 2013 Category: Pharmaceuticals Source Type: news

Bernstein Liebhard LLP Investigating Diabetes Drug Lawsuits Involving...
The Firm is investigating diabetes drug lawsuits on behalf of patients who took Byetta, Januvia, Victoza or similar medications and were diagnosed with pancreatitis, pancreatic cancer or thyroid...(PRWeb June 16, 2013)Read the full story at http://www.prweb.com/releases/diabetes-drug-lawsuit/pancreatic-cancer/prweb10837515.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 16, 2013 Category: Pharmaceuticals Source Type: news

Diabetes drugs may be linked to pancreatic cancer
Conclusion This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas. The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs. However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing eme...
Source: NHS News Feed - June 10, 2013 Category: Consumer Health News Tags: Medication Diabetes QA articles Source Type: news

Diabetes Drug Shows Promise in Parkinson'sDiabetes Drug Shows Promise in Parkinson's
Results of small proof-of-concept trial should spur further interest in funding a larger controlled trial of exenatide in patients with PD. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 23, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Testing Diabetes Drug On Parkinson's Disease Patients
Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the progression of the disease. In this issue of the Journal of Clinical Investigation, Dr. Thomas Foltynie and colleagues at the National Hospital for Neurology and Neurosurgery in London investigated the use of a drug approved for diabetes care, Exenatide, in PD patients... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 22, 2013 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news

Weekly Web Review: ricin, gila monsters, and Hitler’s food taster
Caster beans and ricin: At the ToxTalk podcast, Matt Zuckerman, Jen Carey, and Ed Boyer from the University of Massachusetts toxicology program have a level-headed discussion as to whether or not one should panic if an envelope filled with ricin arrives in the mail. I was especially interested to hear about their recent case of a suicidal man who put 30 castor beans through a blender and swallowed the slurry. Tests for urine ricinine were strongly positive. Consistent with TPR‘s long-held belief that the furor about ricin is much ado about (mostly) nothing, the ensuing nausea, vomiting, and abdominal discom...
Source: The Poison Review - April 28, 2013 Category: Toxicology Authors: Leon Tags: Medical beta blocker poisoning calcium channel blocker toxicity gila monster ricin ToxTalk weekly web review Source Type: news

Report Shows Byetta, Januvia and Other Incretin Mimetic Drugs for Type...
According to the Institute for Safe Medication Practices’ most recent QuarterWatch report, incretin mimetic drugs such as Byetta, Januvia and Victoza may be 25 times more likely to be linked to...(PRWeb April 19, 2013)Read the full story at http://www.prweb.com/releases/Byetta-Januvia-cancer/04/prweb10653663.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 23, 2013 Category: Pharmaceuticals Source Type: news

Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans
Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida. Their findings were published online March 22 in the journal Diabetes.   The researchers, from the Larry L. Hillblom Islet Research Center at UCLA and the Diabetes Center at the University of Florida, found that cell mass was increased approximately 40 percent in the pancreases of deceased organ donors who had Type 2 ...
Source: UCLA Newsroom: Health Sciences - March 26, 2013 Category: Universities & Medical Training Source Type: news

Fate of Taspoglutide, a Weekly GLP-1 Agonist, vs ExenatideFate of Taspoglutide, a Weekly GLP-1 Agonist, vs Exenatide
What factors make this investigational GLP-1 receptor agonist unacceptable for use? Diabetes Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Some Diabetes Drugs Linked To Pancreatitis Risk
Diabetes patients who take the newest class of diabetes drugs have double the risk of being hospitalized with acute pancreatitis, researchers from Johns Hopkins University School of Medicine, Baltimore, reported in JAMA Internal Medicine. The authors explained that the new forms of sugar-control medications prescribed to diabetes patients are called GLP-1 (glucagon-like peptide-1). Examples of such drugs include sitagliptin (Januvia) and exenatide (Byetta)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 1, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news

The Confusion Over A Pair Of Diabetes Drugs And Pancreatitis
Will yet another study about the risk of pancreatitis spell trouble for some diabetes drugs? The latest instance involves a paper that was published in JAMA Internal Medicine and indicates that Merck’s Januvia and Bristol-Myers Squibb’s Byetta can double the risk of developing pancreatitis. Yes, this is the same issue that, over the past few years, has plagued drugs that increase the GLP-1 hormone. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 1, 2013 Category: Pharmaceuticals Authors: Ed Silverman Source Type: news

Editorial: GLP-1 based agents and acute pancreatitis
Source: BMJ Area: News The author of this BMJ editorial discusses a recent study published in JAMA which found that the glucagon-like peptide (GLP)-1-based therapies sitagliptin and exenatide were associated with increased odds of hospitalisation for acute pancreatitis. According to the author, the FDA database carried a signal for acute pancreatitis with exenatide in 2006, a year before the agency alerted clinicians. He states, "Furthermore, all GLP-1 based agents that have been on the market for more than two years have also generated a signal for acute pancreatitis, suggesting a class effect." The regulatory ...
Source: NeLM - News - February 28, 2013 Category: Drugs & Pharmacology Source Type: news

Sitagliptin and exenatide associated with an increased risk of acute pancreatitis
Source: JAMA Internal Medicine Area: News According to a study published in JAMA Internal Medicine, treatment of type 2 diabetes mellitus with the glucagon-like peptide (GLP)-1-based therapies sitagliptin and exenatide was associated with increased odds of hospitalisation for acute pancreatitis.   A large administrative database in the United States  was used to collect data for the  population-based case-control study - adults with type 2 diabetes mellitus aged 18 to 64 years were identified and 1269 hospitalised cases with acute pancreatitis using a validated algorithm and 1269 control subjects matche...
Source: NeLM - News - February 26, 2013 Category: Drugs & Pharmacology Source Type: news

Glucagonlike Peptide 1-Based Therapies Associated With Acute Pancreatitis In Study
JAMA Internal Medicine Study Highlights In a study by Sonal Singh, M.D., M.P.H., of The Johns Hopkins University School of Medicine, Baltimore, and colleagues, treatment with the glucagonlike peptide-1 (GLP-1)-based therapies sitagliptin and exenatide were associated with increased odds of hospitalization for acute pancreatitis in adults with type 2 diabetes mellitus. (Online First) The population-based case-control study used a large administrative database of adults with type 2 diabetes. Researchers identified 1,269 hospitalized cases with acute pancreatitis and 1,269 matched controls... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 25, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news

Newest Diabetes Drugs Linked to Higher Pancreatitis Risk
Patients on Januvia, Byetta twice as likely to develop condition, study says Source: HealthDay Related MedlinePlus Pages: Diabetes Medicines, Pancreatitis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 25, 2013 Category: Consumer Health News Source Type: news

Horizon Scanning: weekly taspoglutide vs. twice daily exenatide for type 2 diabetes
This study, published in Diabetes Care, compared the efficacy and safety of once-weekly taspoglutide with twice-daily exenatide.   Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomised to subcutaneous taspoglutide 10 mg weekly (n = 399), taspoglutide 20 mg weekly (n = 398), or exenatide 10 micrograms twice daily (n = 392) in an open-label, multicentre trial. The primary end point was change in HbA1c after 24 weeks.   The authors reported the following results: . Both doses of taspoglutide reduced HbA1c significantly more than exenat...
Source: NeLM - News - February 22, 2013 Category: Drugs & Pharmacology Source Type: news

d'Oliveira & Associates Now Offers a No Win - No Fee Promise...
The Law Firm of d'Oliveira & Associates Offers "No Win No Fee Promise" For clients injured from the insulin injection Byetta, used to treat Type 2 Diabetes. Byetta has been linked to...(PRWeb February 13, 2013)Read the full story at http://www.prweb.com/releases/2013/2/prweb10394120.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2013 Category: Pharmaceuticals Source Type: news

Diabetes Drug May Offer 'Modest' Weight Loss for Very Obese Teens
Byetta users showed small improvement, but drug is pricey and has side effectsSource: HealthDay Related MedlinePlus Pages: Diabetes Medicines, Obesity in Children, Weight Control (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 5, 2013 Category: Consumer Health News Source Type: news

Diabetes Drug May Help Obese Teens Shed Pounds (CME/CE)
(MedPage Today) -- Treatment with the glucagon-like peptide-1 receptor agonist exenatide (Byetta, Bydureon), which suppresses appetite and increases feelings of satiety, may offer hope to severely overweight teens, researchers reported. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 5, 2013 Category: Endocrinology Source Type: news

Once-Daily GLP-1 Agonist, Lixisenatide, Licensed in EUOnce-Daily GLP-1 Agonist, Lixisenatide, Licensed in EU
Another GLP-1 agonist is entering the type 2 diabetes market, in the form of once-daily lixisenatide, which has been approved in the EU. It will compete with liraglutide and exenatide. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 4, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Addition of Exenatide to Basal Insulin for Type 2 DiabetesAddition of Exenatide to Basal Insulin for Type 2 Diabetes
This study assessed the benefits and risks of adding exenatide, a GLP-1 receptor agonist, in patients with type 2 diabetes who have not gained glycemic control on basal insulin alone. International Journal of Clinical Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Liraglutide edges out exenatide, but GI side effects doubled
Once-daily liraglutide had the edge over once-weekly exenatide in a new head-to-head comparison of the two GLP-1 agonists in type 2 diabetes, but more patients on liraglutide had GI side effects. (Source: theHeart.org)
Source: theHeart.org - January 11, 2013 Category: Cardiology Source Type: news

Liraglutide Edge Over Exenatide, but GI Side Effects DoubledLiraglutide Edge Over Exenatide, but GI Side Effects Doubled
Once-daily liraglutide had the edge over once-weekly exenatide in a new head-to-head comparison of the two GLP-1 agonists in type 2 diabetes, but more patients on liraglutide had gastrointestinal side effects. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 11, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Exenatide more effective than insulin detemir: study
NEW YORK (Reuters Health) - Exenatide is more effective than insulin detemir when added to oral glucose-lowering therapies, European researchers say. (Source: Modern Medicine)
Source: Modern Medicine - January 9, 2013 Category: Journals (General) Source Type: news

Once-weekly exenatide versus once- or twice-daily insulin detemir in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
This study is the first to compare EQW and insulin detemir, with respect to glycaemic control, body weight, lipids, safety, tolerability, and patient-reported outcomes in patients with type 2 diabetes whose diabetes was inadequately controlled with metformin (with or without sulfonylureas). Patients were randomised to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma ... (Source: NeLM - News)
Source: NeLM - News - January 4, 2013 Category: Drugs & Pharmacology Source Type: news